Payment overview · 2025
General Payments
$147.61
6 reported records · 4 companies
Healthcare provider profile · identity verified
Brandon King, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · GORE, OK · NPI 1609173038
Verified facts
What the public records show
CMS Open Payments records show Brandon King, D.O. received $147.61 in general payments during 2025 across 6 reported records.
UCB, Inc. accounted for 59.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| UCB, Inc. | Unresolved — no canonical attribution shown | $87.07 | 59.0% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $21.46 | 14.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $20.32 | 13.8% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $18.76 | 12.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $147.61 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $87.07 | 3 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $21.46 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $20.32 | 1 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $18.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1272 | 124 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1183 | 144 |
| Lisinopril | Lisinopril | 841 | 125 |
| Pantoprazole Sodium | Pantoprazole Sodium | 699 | 90 |
| Escitalopram Oxalate | Escitalopram Oxalate | 622 | 60 |
| Famotidine | Famotidine | 580 | 51 |
| Metformin Hcl | Metformin Hcl | 526 | 66 |
| Meloxicam | Meloxicam | 492 | 67 |
| Lamotrigine | Lamotrigine | 459 | 41 |
| Potassium Chloride | Potassium Chloride | 434 | 61 |
| Diclofenac Sodium | Diclofenac Sodium | 421 | 61 |
| Memantine Hcl | Memantine Hcl | 407 | 37 |
| Propranolol Hcl | Propranolol Hcl | 406 | 39 |
| Omeprazole | Omeprazole | 402 | 67 |
| Levetiracetam | Levetiracetam | 383 | 42 |
| Clozapine | Clozapine | 347 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 322 | 45 |
| Amlodipine Besylate | Amlodipine Besylate | 307 | 64 |
| Naltrexone Hcl | Naltrexone Hcl | 307 | 27 |
| Clonidine Hcl | Clonidine Hcl | 294 | 31 |
| Simvastatin | Simvastatin | 254 | 29 |
| Gabapentin | Gabapentin | 249 | 45 |
| Furosemide | Furosemide | 248 | 43 |
| Losartan Potassium | Losartan Potassium | 248 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 247 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 194 | 73 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 183 | 27 |
| Riluzole | Riluzole | 176 | 20 |
| Desmopressin Acetate | Desmopressin Acetate | 175 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 175 | 29 |
| Montelukast Sodium | Montelukast Sodium | 160 | 25 |
| Topiramate | Topiramate | 159 | 12 |
| Prednisone | Prednisone | 150 | 74 |
| Olanzapine | Olanzapine | 149 | 14 |
| Lactulose | Lactulose | 136 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 134 | 25 |
| Risperidone | Risperidone | 128 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 123 | 18 |
| Sertraline Hcl | Sertraline Hcl | 120 | 26 |
| Glipizide | Glipizide | 118 | 18 |
| Divalproex Sodium | Divalproex Sodium | 115 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 110 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 108 | 60 |
| Pindolol | Pindolol | 107 | 14 |
| Trazodone Hcl | Trazodone Hcl | 104 | 23 |
| Allopurinol | Allopurinol | 101 | 18 |
| Latanoprost | Latanoprost | 101 | 14 |
| Ozempic | Semaglutide | 100 | 15 |
| Donepezil Hcl | Donepezil Hcl | 96 | 12 |
| Linzess | Linaclotide | 96 | suppressed |
| Celecoxib | Celecoxib | 94 | 17 |
| Trintellix | Vortioxetine Hydrobromide | 89 | suppressed |
| Glipizide Er | Glipizide | 87 | 19 |
| Ibuprofen | Ibuprofen | 87 | 36 |
| Cephalexin | Cephalexin | 86 | 66 |
| Lovastatin | Lovastatin | 86 | suppressed |
| Januvia | Sitagliptin Phosphate | 85 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 84 | 12 |
| Divalproex Sodium Er | Divalproex Sodium | 83 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 81 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 80 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 80 | 22 |
| Lithium Carbonate | Lithium Carbonate | 79 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 78 | 17 |
| Cryselle | Norgestrel-Ethinyl Estradiol | 77 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 77 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 76 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 75 | 33 |
| Glycopyrrolate | Glycopyrrolate | 75 | suppressed |
| Nystatin | Nystatin | 71 | 26 |
| Baclofen | Baclofen | 69 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 69 | 13 |
| Xarelto | Rivaroxaban | 69 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 67 | 19 |
| Doxazosin Mesylate | Doxazosin Mesylate | 66 | suppressed |
| Acetylcysteine | Acetylcysteine | 62 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 62 | suppressed |
| Vraylar | Cariprazine Hcl | 62 | suppressed |
| Carvedilol | Carvedilol | 61 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 61 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 59 | suppressed |
| Gemtesa | Vibegron | 58 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 55 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 55 | suppressed |
| Eliquis | Apixaban | 53 | 15 |
| Finasteride | Finasteride | 53 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 53 | 35 |
| Azithromycin | Azithromycin | 52 | 47 |
| Mupirocin | Mupirocin | 52 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 50 | suppressed |
| Sucralfate | Sucralfate | 49 | suppressed |
| Jardiance | Empagliflozin | 48 | 13 |
| Bupropion Xl | Bupropion Hcl | 47 | suppressed |
| Mirtazapine | Mirtazapine | 47 | suppressed |
| Atenolol | Atenolol | 46 | suppressed |
| Lumigan | Bimatoprost | 43 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 41 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 40 | suppressed |
| Caplyta | Lumateperone Tosylate | 40 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | suppressed |
| Glimepiride | Glimepiride | 38 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 38 | suppressed |
| Trulicity | Dulaglutide | 38 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 37 | suppressed |
| Ramelteon | Ramelteon | 36 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 34 | 11 |
| Methylprednisolone | Methylprednisolone | 34 | 29 |
| Morphine Sulfate Er | Morphine Sulfate | 34 | suppressed |
| Naproxen | Naproxen | 33 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 32 | suppressed |
| Lacosamide | Lacosamide | 31 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Alprazolam | Alprazolam | 29 | suppressed |
| Amoxicillin | Amoxicillin | 29 | 25 |
| Tresiba Flextouch U-200 | Insulin Degludec | 29 | suppressed |
| Carbamazepine | Carbamazepine | 28 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 28 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 28 | 24 |
| Tobramycin | Tobramycin | 28 | suppressed |
| Loperamide | Loperamide Hcl | 26 | 20 |
| Mono-Linyah | Norgestimate-Ethinyl Estradiol | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 23 |
| Clonazepam | Clonazepam | 25 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 24 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 24 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 21 |
| Arnuity Ellipta | Fluticasone Furoate | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Norethindrone-E.Estradiol-Iron | Norethindrone-E.Estradiol-Iron | 22 | suppressed |
| Nortrel | Norethindrone-Ethin. Estradiol | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | 16 |
| Clomipramine Hcl | Clomipramine Hcl | 21 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Norethindrone | Norethindrone | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 19 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 13 |
| Bumetanide | Bumetanide | 18 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 18 | suppressed |
| Norethindron-Ethinyl Estradiol | Norethindrone Ac/Eth Estradiol | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Briviact | Brivaracetam | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Kelnor 1-50 | Ethynodiol D-Ethinyl Estradiol | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Aurovela 24 Fe | Norethindrone-E.Estradiol-Iron | 13 | suppressed |
| Austedo Xr | Deutetrabenazine | 13 | suppressed |
| Cabergoline | Cabergoline | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Invokana | Canagliflozin | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | 12 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Sulfasalazine | Sulfasalazine | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Aristada | Aripiprazole Lauroxil | 11 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 11 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 11 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Lybalvi | Olanzapine/Samidorphan Malate | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Prenatal Vitamin Plus Low Iron | Pnv,calcium 72/Iron/Folic Acid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $147.61 · 6 records | UCB, Inc. | EPIDIOLEX, Nayzilam, REXULTI, WATCHMAN Access System | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Otsuka America Pharmaceutical, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error